Circulating miR-142-3p levels in patients with systemic sclerosis

Clinical and Experimental Dermatology

Volumn 37, Issue 1, 2012, Pages 34-39

  Makino, K ^a   Jinnin, M ^a   Kajihara, I ^a   Honda, N ^a   Sakai, K ^a   Masuguchi, S ^a   Fukushima, S ^a   Inoue, Y ^a   Ihn, H ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 142-3P; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SCLERODERMA; SUBLINGUAL FRENULUM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC;

EID: 84355161738     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04158.x     Document Type: Article

References (21)

1. Korn J,. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1989; 1: 479-84. (Pubitemid 20125933)
2. Mauch C, Kreig T,. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am 1990; 16: 93-107. (Pubitemid 20116147)
3. Mauch C, Kozlowska E, Eckes B, et al. Altered regulation of collagen metabolism in scleroderma fibroblasts grown within three-dimensional collagen gels. Exp Dermatol 1992; 1: 185-90.
4. Jelaska A, Arakawa M, Broketa G, et al. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 1996; 39: 1338-46. (Pubitemid 26270093)
5. Leroy E, Smith E, Kahaleh M, et al. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Arthritis Rheum 1989; 32: 817-25. (Pubitemid 19181003)
6. LeRoy E,. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 880-9.
7. Jimenez S, Feldman G, Bashey R, et al. Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts. Biochem J 1986; 237: 837-43. (Pubitemid 16003787)
8. Kikuchi K, Hartl C, Smith E, et al. Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts: insensitivity to TGF beta 1 stimulation. Biochem Biophys Res Commun 1992; 187: 45-50.
9. Lyons R, Gentry L, Purchio A, et al. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110: 1361-7.
10. Ihn H,. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp (Warsz) 2002; 50: 325-31. (Pubitemid 35434568)
11. Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alphaVbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006; 168: 499-510. (Pubitemid 43271148)
12. Murphy-Ullrich J, Poczatek M,. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11: 59-69. (Pubitemid 30169726)
13. Ihn H, Yamane K, Kubo M, et al. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001; 44: 474-80.
14. Asano Y, Ihn H, Yamane K, et al. Involvement of alphaVbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005; 52: 2897-905. (Pubitemid 41369121)
15. Lewis B, Burge C, Bartel D,. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20. (Pubitemid 40094598)
16. LeRoy E, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5. (Pubitemid 18073738)
17. Ihn H, Sato S, Fujimoto M, et al. Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis. Clin Exp Immunol 1996; 105: 475-9. (Pubitemid 26297893)
18. Maricq H, McGregor A, Diat F, et al. Major clinical diagnoses found among patients with Raynaud phenomenon from the general population. J Rheumatol 1990; 17: 1171-6. (Pubitemid 20334694)
19. Ihn H, Sato S, Tamaki T, et al. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 1992; 284: 391-5. (Pubitemid 23009895)
20. Maricq H, Weinrich M, Keil J, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32: 998-1006. (Pubitemid 19218379)
21. Kroh E, Parkin R, Mitchell P, et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50: 298-301.